CRS:NYSECarpenter Technology Corporation Analysis
Data as of 2026-06-07 - not real-time
$483.60
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Carpenter Technology is trading well above its short‑term and medium‑term moving averages, and the MACD remains in bullish territory, suggesting continued upward momentum despite an RSI that points to near‑overbought conditions. The stock sits near a key resistance level, with a solid support cushion well below the current price, while beta and recent volatility indicate heightened sensitivity to market swings.
Fundamentally, the company commands a premium valuation—its price‑to‑earnings multiple far exceeds the industry average and the discounted cash‑flow estimate is dramatically lower than the market price, implying the stock is overvalued in the near term. Nevertheless, revenue is growing at double‑digit rates, margins are healthy, cash flow is robust, and the modest dividend payout signals sustainability, positioning CRS as a growth‑oriented name with a low‑risk dividend profile.
Fundamentally, the company commands a premium valuation—its price‑to‑earnings multiple far exceeds the industry average and the discounted cash‑flow estimate is dramatically lower than the market price, implying the stock is overvalued in the near term. Nevertheless, revenue is growing at double‑digit rates, margins are healthy, cash flow is robust, and the modest dividend payout signals sustainability, positioning CRS as a growth‑oriented name with a low‑risk dividend profile.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near 52‑week high and key resistance
- Elevated RSI and higher beta increasing pull‑back risk
- Valuation gap between market price and DCF estimate
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Consistent revenue and margin expansion
- Strong operating and free cash flow generation
- Low dividend payout supporting financial flexibility
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Long‑term demand in aerospace, defense, and medical markets
- Robust return on equity and solid balance sheet
- Sustainable dividend with ample cash coverage
Key Metrics & Analysis
Financial Health
Revenue Growth11.60%
Profit Margin15.82%
P/E Ratio51.0
ROE24.89%
ROA11.33%
Debt/Equity33.82
P/B Ratio11.6
Op. Cash Flow$623.0M
Free Cash Flow$300.7M
Industry P/E30.2
Technical Analysis
TrendBullish
RSI65.0
Support$390.00
Resistance$500.16
MA 20$447.23
MA 50$432.11
MA 200$342.80
MACDBullish
VolumeStable
Fear & Greed Index83.02
Valuation
Fair Value$121.95
Target Price$459.50
Upside/Downside-4.98%
GradeOvervalued
TypeGrowth
Dividend Yield0.17%
Risk Assessment
Beta1.43
Volatility42.38%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
ZIONP
Zions Bancorporation N.A. - Depositary Shares each representing a 1/40th ownership interest in a share of Series A Floating-Rate Non-Cumulative Perpetual Prefer
STOCKZION
Zions Bancorporation N.A.
STOCKYOU
Clear Secure, Inc.
STOCKABCL
AbCellera Biologics Inc.
STOCKWETH
Wetouch Technology Inc.
STOCKSOPA
Society Pass Incorporated
STOCKThis analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.